Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LS1681: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma

NCT03003546 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03003546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03003546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LS1681: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2019
Completion date
May 16, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent aggressive non-hodgkin lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, refractory aggressive non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory small lymphocytic lymphoma